{"id":61584,"date":"2025-07-15T19:05:02","date_gmt":"2025-07-15T17:05:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/"},"modified":"2025-07-15T19:05:02","modified_gmt":"2025-07-15T17:05:02","slug":"aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/","title":{"rendered":"Aledade Names Lalith Vadlamannati, Ph.D., as Chief Technology Officer"},"content":{"rendered":"
\n

\nAccomplished tech leader brings more than two decades of experience in engineering and technology innovation<\/i><\/p>\n

BETHESDA, Md.–(BUSINESS WIRE)–Aledade<\/a>, the nation\u2019s largest network of independent primary care, announced today the appointment of Lalith Vadlamannati, Ph.D., as its new chief technology officer (CTO).<\/p>\n

<\/a>
<\/a><\/p>\n

\nVadlamannati brings over two decades of experience in leading technology transformation and innovation across diverse industries, including health technology, eCommerce and supply chain management. Vadlamannati<\/a> will lead the development and execution of Aledade\u2019s technology strategy and accelerate the delivery of innovative tools that drive clinician satisfaction and patient outcomes for Aledade partners. Aledade’s technology has earned a Best in KLAS designation and 88% of current partners rate Aledade\u2019s products and services as high quality. Vadlamannati will report to Aledade co-founder and CEO Farzad Mostashari, M.D.<\/p>\n

\n\u201cLalith\u2019s extensive experience as a technology leader and his groundbreaking work in AI-driven health care solutions make him the perfect fit to guide our tech vision moving forward,\u201d Mostashari said. \u201cHis experience and insights will be critical to helping Aledade advance our mission to transform health care that is good for patients, primary care partners and society as a whole.\u201d<\/p>\n

\nVadlamannati most recently served as CTO at Hinge Health where he spearheaded advancements in personalized and automated musculoskeletal care through AI and wearable technology. Before joining Hinge Health, Vadlamannati was vice president of engineering at Amazon, where he led the international expansion program for Amazon eCommerce. There, Vadlamannati built and scaled a high-performing technology organization that enhanced global eCommerce platforms and built cutting-edge AI and machine learning solutions for consumer and business services in India and emerging markets. He holds a Ph.D., from the University of Pittsburgh and a Bachelor of Technology degree from the Indian Institute of Technology Bombay.<\/p>\n

\n\u201cWhat drew me to Aledade was its mission to improve the health care system and its commitment to providing innovative technology solutions to advance this work,\u201d Vadlamannati said. \u201cI am excited to join this incredible team and look forward to being part of Aledade\u2019s exciting future growth by leveraging AI, machine learning and other emerging technologies to bring about a more efficient health care system for those whom we serve.\u201d<\/p>\n

\nAbout Aledade<\/b><\/p>\n

\nAledade, a public benefit corporation<\/a>, is the largest network of independent primary care in the country, helping independent practices, health centers and clinics deliver better care to their patients and thrive in value-based care. Through its proven, scalable model, which includes cutting-edge data analytics, user-friendly guided workflows, health care policy expertise, strong payer relationships and integrated care solutions, Aledade empowers physicians to succeed financially by keeping people healthy. Together with more than 2,400 practices, federally-qualified health centers and community health centers in 46 states and the District of Columbia, Aledade shares in the risk and reward across more than 200 value-based contracts representing nearly 3.0 million patient lives under management. To learn more, visit www.aledade.com<\/a> or follow on X (Twitter)<\/a>, Facebook<\/a> or LinkedIn<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nHiran Ratnayake
\n
Director of External Communications
\n
(302) 299-3562
\n
Request an Interview<\/a>
Visit our Newsroom<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Accomplished tech leader brings more than two decades of experience in engineering and technology innovation BETHESDA, Md.–(BUSINESS WIRE)–Aledade, the nation\u2019s largest network of independent primary care, announced today the appointment of Lalith Vadlamannati, Ph.D., as its new chief technology officer (CTO). Vadlamannati brings over two decades of experience in leading technology transformation and innovation across … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61584","6":"format-standard","7":"category-industry"},"yoast_head":"\nAledade Names Lalith Vadlamannati, Ph.D., as Chief Technology Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aledade Names Lalith Vadlamannati, Ph.D., as Chief Technology Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Accomplished tech leader brings more than two decades of experience in engineering and technology innovation BETHESDA, Md.–(BUSINESS WIRE)–Aledade, the nation\u2019s largest network of independent primary care, announced today the appointment of Lalith Vadlamannati, Ph.D., as its new chief technology officer (CTO). Vadlamannati brings over two decades of experience in leading technology transformation and innovation across ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-15T17:05:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250715990332\/en\/2455194\/22\/Aledade_Logo_Blue_%282%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Aledade Names Lalith Vadlamannati, Ph.D., as Chief Technology Officer\",\"datePublished\":\"2025-07-15T17:05:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\\\/\"},\"wordCount\":514,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250715990332\\\/en\\\/2455194\\\/22\\\/Aledade_Logo_Blue_%282%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\\\/\",\"name\":\"Aledade Names Lalith Vadlamannati, Ph.D., as Chief Technology Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250715990332\\\/en\\\/2455194\\\/22\\\/Aledade_Logo_Blue_%282%29.jpg\",\"datePublished\":\"2025-07-15T17:05:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250715990332\\\/en\\\/2455194\\\/22\\\/Aledade_Logo_Blue_%282%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250715990332\\\/en\\\/2455194\\\/22\\\/Aledade_Logo_Blue_%282%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aledade Names Lalith Vadlamannati, Ph.D., as Chief Technology Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aledade Names Lalith Vadlamannati, Ph.D., as Chief Technology Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/","og_locale":"en_US","og_type":"article","og_title":"Aledade Names Lalith Vadlamannati, Ph.D., as Chief Technology Officer - Pharma Trend","og_description":"Accomplished tech leader brings more than two decades of experience in engineering and technology innovation BETHESDA, Md.–(BUSINESS WIRE)–Aledade, the nation\u2019s largest network of independent primary care, announced today the appointment of Lalith Vadlamannati, Ph.D., as its new chief technology officer (CTO). Vadlamannati brings over two decades of experience in leading technology transformation and innovation across ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/","og_site_name":"Pharma Trend","article_published_time":"2025-07-15T17:05:02+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250715990332\/en\/2455194\/22\/Aledade_Logo_Blue_%282%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Aledade Names Lalith Vadlamannati, Ph.D., as Chief Technology Officer","datePublished":"2025-07-15T17:05:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/"},"wordCount":514,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250715990332\/en\/2455194\/22\/Aledade_Logo_Blue_%282%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/","url":"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/","name":"Aledade Names Lalith Vadlamannati, Ph.D., as Chief Technology Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250715990332\/en\/2455194\/22\/Aledade_Logo_Blue_%282%29.jpg","datePublished":"2025-07-15T17:05:02+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250715990332\/en\/2455194\/22\/Aledade_Logo_Blue_%282%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250715990332\/en\/2455194\/22\/Aledade_Logo_Blue_%282%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/aledade-names-lalith-vadlamannati-ph-d-as-chief-technology-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Aledade Names Lalith Vadlamannati, Ph.D., as Chief Technology Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61584"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61584\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}